Dabigatran in atrial fibrillation: Pharmacology and clinical trials

Journal of Interventional Cardiac Electrophysiology

Volumn 32, Issue 3, 2011, Pages 173-180

  Ezekowitz, Michael D ^a   Nagarakanti, Rangadham ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Dabigatran; Randomized clinical trials

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; DABIGATRAN; DIGOXIN; RIFAMPICIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVERSION; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84855611604     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-011-9593-x     Document Type: Conference Paper

References (40)

1. Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P., et al. (2006). Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 114, 119-125. (Pubitemid 44420743)
2. Go, A. S., Hylek, E. M., Borowsky, L. H., Phillips, K. A., Selby, J. V., & Singer, D. E. (1999). Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Annals of Internal Medicine, 131, 927-934. (Pubitemid 30005032)
3. Boulanger, L., Kim, J., Friedman, M., Hauch, O., Foster, T., & Menjin, J. (2006). Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. International Journal of Clinical Practice, 60(3), 258-264. (Pubitemid 43337604)
4. Stroke Prevention in Atrial Fibrillation Investigators. (1996). Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet, 348, 633-638.
5. Petersen, P., Boysen, G., Godtfredsen, J., Anderson, E. D., & Anderson, B. (1989). Placebo-controlled, randomised trial of warfarin and ASA for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet, 1(8631), 175-179. (Pubitemid 19038801)
6. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. (1990). The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. The New England Journal of Medicine, 323(22), 1505-1511.
7. Stroke Prevention in Atrial Fibrillation Investigators. (1991). Stroke prevention in atrial fibrillation study. Final results. Circulation, 84(2), 527-539.
8. Ezekowitz, M. D., Bridgers, S. L., James, K. E., Carliner, N. H., Colling, C. L., & Gornick, C. C. (1992). Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. The New England Journal of Medicine, 327(14), 1406-1412.
9. Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. (1991). Canadian Atrial Fibrillation Anticoagulation (CAFA) study. Journal of the American College of Cardiology, 18, 349-355.
10. Mant, J., Hobbs, F. D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA) : a randomised controlled trial. Lancet, 370, 493-503. (Pubitemid 47212371)
11. Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., et al. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W) : a randomised controlled trial. Lancet, 367, 1903-1912.
12. Gross, C. P., Vogel, E. W., Dhond, A. J., Marple, C. B., Edwards, R. A., Hauch, O., et al. (2003). Factors influencing physicians' reported use of anticoagulation therapy in non-valvular atrial fibrillation: a cross-sectional survey. Clinical Therapeutics, 25(6), 1750-1764. (Pubitemid 36801946)
13. Monette, J., Gurwitz, J. H., Rochon, P. A., & Avorn, J. (1997). Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. Journal of the American Geriatrics Society, 45, 1060-1065. (Pubitemid 27377551)
14. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139-1151.
15. Di Nisio, M., Middeldorp, S., & Buller, H. R. (2005). Direct thrombin inhibitors. The New England Journal of Medicine, 353(10), 1028-1104.
16. Stangier, J. (2008). Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetics, 47(5), 285-295. (Pubitemid 351508116)
17. Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., et al. (2007). Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). The American Journal of Cardiology, 100, 1419-1426. (Pubitemid 47576022)
18. Nagarakanti, R., Ezekowitz, M. D., Parcham-Azad, K., Reilly, P. A., Nehmiz, G., Lionetti, D. A., et al. (2008). Long-term open label extension of the prevention of embolic and thrombotic events on dabigatran in atrial fibrillation (PETRO-Ex study). Circulation, 118, S 922. Abstract no. 4629.
19. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly P. A., Wallentin, L., Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. (2010). Newly identified events in the RE-LY trial. The New England Journal of Medicine, 363(19), 1875-1876.
20. Hylek, E. M., Frison, L., Henault, L. E., & Cupples, A. (2008). Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke, 39, 3009-3014.
21. Hylek, E. M., Evans-Molina, C, Shea, C, Henault, L. E., & Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 115, 2689-2696. (Pubitemid 46842784)
22. Ezekowitz, M. D., Connolly, S., Parekh, A., Reilly, P. A., Varrone, J., Wang, S., et al. (2009). Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal, 157(5), 805-810.e1-2
23. Jones, M., McEwan, P., Morgan, C. L., Peters, J. R., Goodfellow, J., & Currie, C. J. (2005). Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart, 91, 472-477. (Pubitemid 40432773)
24. Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., et al. (2003). Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. The New England Journal of Medicine, 349, 1019-1026. (Pubitemid 37087616)
25. Oake, N., Fergusson, D. A., Forster, A. J., & Van Walraven, C. (2007). Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. Canadian Medical Association Journal, 176, 1589-1594. (Pubitemid 46868607)
26. Wallentin, L., Yusuf, S., Ezekowitz, M., Alings, M., Flather, M., Franzosi, M. G, et al. (2010). Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, 376(9745), 975-983.
27. Resnekov, L., & McDonald, L. (1967). Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. British Heart Journal, 29, 926-936.
28. Lown, B., Perlroth, M. G, Kaidbey, S., Abe, T., & Harken, D. E. (1963). "Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. The New England Journal of Medicine, 269, 325-331.
29. Jensen, J. B., Humphries, J. O., Kouwenhoven, W. B., & Jude, J. R. (1965). Electroshock for atrial flutter and atrial fibrillation: follow-up studies on 50 patients. Journal of the American Medical Association, 194, 1181-1184.
30. Bjerkelund, C. J., & Orning, O. M. (1969). The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. The American Journal of Cardiology, 23, 208-216.
31. Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation, 114, e257-e354.
32. Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. S., et al. (2008). Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 546S-592S. (Pubitemid 351892972)
33. Klein, A. L., Grimm, R. A., Murray, R. D., Apperson-Hansen, C., Asinger, R. W., Black, I. W., et al. (2001). Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. The New England Journal of Medicine, 344(19), 1411-1420. (Pubitemid 32402097)
34. Atrial Fibrillation Investigators. (1994). Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from 5 randomized controlled trials. Archives of Internal Medicine, 154, 1449-1457.
35. Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Journal of the American Medical Association, 285, 2864-2870. (Pubitemid 32537350)
36. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010). Guidelines for the management of atrial fibrillation. European Heart Journal, 31, 2369-2429.
37. Oldgren, J., Alings, M., Darius, H., Eikelboom, J., Ezekowitz, M. D., Parekh, A., et al. (2010). Dabigatran versus warfarin in atrial fibrillation with low, moderate and high CHADS2 score: A RELY subgroup analysis. Journal of the American College of Cardiology, 55 (10 A), E2. Abstract.
38. Oldgren, J., Ezekowitz, M. D., Alings, M., Diener, H.-C., Reilly, P. A., Yusuf, S., et al. (2011). Dabigatran versus warfarin and impact of CHADS2VASc score on outcome in atrial fibrillation patients: a RELY subgroup analysis. Journal of the American College of Cardiology, 15(14), E7. Abstract.
39. Lee, W. M., Larrey, D., Olsson, R., Lewis, J. H., Keisu, M., Auclert, L., et al. (2005). Hepatic findings in long-term clinical trials of ximelagatran. Drug Safety, 28, 351-370. (Pubitemid 40545769)
40. Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., et al. (2011). Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals of Internal Medicine, 154(1), 1-11.